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A B S T R A C T
 
Immune thrombocytopenic purpura is the most common autoimmune hematologic 
disease, affecting individuals of different ages. Recently, the bacterium Helicobacter pylori 
entered the list of causes of immune thrombocytopenic purpura. Here we present the 
case of a 55-year-old female patient with low platelet counts initially attributed to chronic 
vaginal bleeding. As corticosteroid therapy was ineffective she was treated for H. pylori 
infection. Within four weeks the patient had a platelet count of 87.17 ×109/L accompanied 
by clinical improvement of the symptoms.
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Introduction
Immune thrombocytopenic purpura (ITP) is the most 
common autoimmune hematologic disease, affecting 
individuals of different ages. The former name (‘idiopathic’ 
thrombocytopenic purpura) was used because, in most cases, 
the underlying cause was unknown. In recent decades, the 
list of causative agents has grown considerably and the term 
idiopathic is used less often. The recent entry of the bacterium 
Helicobacter pylori, the agent responsible for the most common 
chronic human infection in the world, in this list of causes has 
been the subject of several studies.1
H. pylori, a Gram-negative microaerophilic commensal 
bacterium that colonizes the human stomach,  is globally 
known as a causative agent of gastritis, peptic ulcers and a 
risk factor for the development of gastric cancer and mucosa-
associated lymphoid tissue lymphoma. Infection has also 
been associated to non-digestive diseases such as coronary 
heart disease, acne rosacea, chronic idiopathic urticaria and 
autoimmune diseases (rheumatoid arthritis, thyroiditis, 
Sjogren’s syndrome and Henoch-Schonlein purpura).2 The 
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prevalence of H. pylori is variable in the population, reaching 
up to 80% but, in general, is less frequent in ITP patients.2
The relationship between H. pylori infection and ITP was 
first described in 1998, by an Italian group that reported a 
significant increase in the platelet numbers in eight of 11 
patients in whom the bacterium was eradicated.3 In recent 
years, several studies have also shown that H. pylori eradication 
in infected patients with ITP could lead to a substantial and 
persistent increase in platelet counts in over half of the 
patients treated.
Case report
A 55-year-old female patient was diagnosed with ITP 10 years 
ago. Previously, the patient had been hospitalized due to severe 
thrombocytopenia. She was then treated with corticosteroids 
(1 mg/kg Prednisone) and had a satisfactory response. After 
that, she did not need to use this medication for a long time. 
Her first hospitalization was in another facility. There was 
little information on exams, just the patient’s report. She was 
asymptomatic until May 2012 when she was admitted to the 
University Hospital, complaining of asthenia for eight days. 
Her platelet count was 56 × 109/L and hemoglobin 5.84 g/dL 
with microcytic hypochromic anemia. During hospitalization, 
treatment was conducted with 1 mg/kg prednisone, with 
which she showed no clinical or laboratory improvement. Iron 
deficiency anemia was confirmed by ferritin levels; this was 
attributed to chronic vaginal bleeding.
Thus, with no response to initial corticosteroid therapy, she 
was prescribed pulse therapy of 1g methylprednisolone per 
day for three days, followed by 400 mg/kg immunoglobulin 
per day for five days. Again there was no clinical or laboratory 
improvement and the patient remained thrombocytopenic 
15 days after completion of pulse therapy. The karyotype 
and immunophenotype of bone marrow were normal. A 
myelogram showed no significant changes. Serology for 
human immunodeficiency virus (HIV), hepatitis B and 
hepatitis C were negative as were fluorescent antibody 
virus neutralization assays and immunoglobulin G (IgG) and 
immunoglobulin M (IgM) for anticardiolipin antibodies. As 
the patient’s platelet count was less than 100 × 109/L, upper 
gastrointestinal endoscopy was not indicated.
Based on reports of a positive urease test during the previous 
endoscopy, but with no other abnormalities, treatment for H. 
pylori infection was carried out for 14 days. The treatment was 
initiated after a positive IgG serology for H. pylori because there 
was no increase in the platelet levels 15 days after the end of 
the corticosteroid and immunoglobulin treatment. A breath 
test was not performed as it was unavailable in the facility. An 
increase in the platelet count of 22.32 × 109/L was observed in 
seven days after the end of the eradication treatment using 
medication scheme 1 (clarithromycin, amoxicillin and proton 
pump inhibitor) and four weeks later the patient had a platelet 
count of 87.17 × 109/L with clinical improvement (Figure 1). 
Subsequently, another endoscopy was performed and the urease 
test was negative. The patient remains in remission 15 months 
after completing treatment, with a platelet count of 178 × 109/L.
Many interpretations have been suggested for the 
pathogenic mechanism, but the phenomenon is still poorly 
understood.1,2 Studies show that the outcome of bacterial 
eradication may depend on genetic factors of the host, on 
environmental factors or even on the H. pylori strain.2 Of the 
several hypotheses on the mechanism by which the bacterium 
could cause ITP, the most accepted is molecular mimicry; that 
is, the bacterium induces the production of antibodies against 
antigens of its surface and, thus there is a cross-reaction 
against multiple platelet glycoprotein antigens.5
In some patients with chronic ITP, infections are associated 
with the exacerbation of thrombocytopenia.6 
The main schemes prescribed to eradicate the H. pylori 
bacterium are relatively simple, accessible and rarely have 
any side effects. Extensive studies have shown a significant 
relationship between bacterial eradication and improvement 
in platelet counts. Thus, it seems reasonable to investigate H. 
pylori in ITP patients, especially in populations with a high 
prevalence of infections by this bacterium.5
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Figure 1 – Mean platelet count response to the eradication of 
Helicobacter pylori bacteria. The treatment to eradicate H. pylori 
was carried out in June 2012, and, from then on, there was a great 
increase in the platelet count.
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